Matthew MorantzMatthewMorantz
Associate, Complex Litigation
Matthew Morantz is an associate in the Litigation Department of Paul Hastings and is based in the firm’s New York office. His practice spans high-stakes trial and appellate litigation in federal and state courts, as well as international arbitration, with experience across industries including pharmaceuticals, biotechnology, construction, infrastructure, mining, energy, manufacturing, technology, real estate, cryptocurrency and financial services. He has handled matters involving breach of contract, fiduciary duties, intellectual property, antitrust, civil RICO claims, government enforcement actions, and other complex commercial and transnational issues.
Representing a Japanese pharmaceutical company in a multibillion-dollar ICC arbitration arising from a licensing dispute.
Representing a Japanese pharmaceutical company in a multibillion-dollar AAA/ICDR arbitration, with parallel U.S. court litigation, concerning IP rights under a cross-border collaboration and licensing agreement.
- Future Leader
Lexology Arbitration Report (2024, 2025, 2026)
“Chapter 12: Tribunal-Mandated Conferencing of Valuation Experts in Investment Arbitration,” Investment Treaty Arbitration and International Law, Author
2019
“On the edge of your CETA: new developments in ISDS reform,” Practical Law, Co-Author
2016
“Synthesis, Nanostructural and Electronic Characterization of Anthracenedicarboximide Derivatives,” Trends in Nanotechnology International Conference, Author
2010
“Scalable, Single-Step Strategy Generates Processable Nacre-Mimetic Films with Remarkable Materials Properties,” Materials Research Society Bulletin, Author
2010
Past Co-Chair
International Council for Commercial Arbitration Under-40 Section (Young ICCA) (2020-22)
Past Task Force Member
ICC Commission on Arbitration and ADR (2023-24)